- ►diabetesjournals.org F Porcellati, P Rossetti, NR Busciantella, S … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—With glargine, plasma glucose remained at 103 ± 3.6 mg/dl up to 24 h,
and all subjects completed the study. Plasma glucose increased progressively
after 16 h with detemir, and only eight subjects (33%) completed the study ... Cited by 41 - Related articles - BL Direct - All 7 versions
T Heise, TR Pieber - Diabetes Obes Metab, 2007 - journals.pcommed.com While the advantages of the two basal insulin analogues, glargine and detemir,
over neutral protamine Hagedorn are well established, the relative merit of the
two compared with each other has been a matter of some controversy. The two ... Cited by 46 - Related articles - View as HTML - All 4 versions
- ►diabetesjournals.org F Porcellati, P Rossetti, NB Ricci, S … - Diabetes Care, 2007 - Am Diabetes Assoc Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine
(1) are superior to those of insulin NPH (2–9). In the clinical setting, this
translates into lower risk of nocturnal hypoglycemia (10–13), lower A1C ( ... Cited by 14 - Related articles - BL Direct - All 6 versions
O Klein, J Lynge, L Endahl, B Damholt, L … - Diabetes Obes Metab, 2007 - interscience.wiley.com Methods: Twenty-seven insulin-treated men with type 2 diabetes [body mass index
30.8 ± 2.6 kg/m 2 (mean ± sd), haemoglobin A 1c 7.6 ± 1.1%] were enrolled in
this randomized, double-blind trial and participated in six euglycaemic ... Cited by 71 - Related articles - All 4 versions
- ►pipex.com [PDF] RR Holman, KI Thorne, AJ Farmer, MJ Davies, … - New England Journal of Medicine, 2007 - content.nejm.org From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and
Metabolism (RRH, KIT, AJF, JFK, SP, JCL) and the Department of Primary Health
Care (AJF), University of Oxford, Oxford; and the Department of Cardiovas- ... Cited by 133 - Related articles - BL Direct - All 12 versions
- ►leicestershirediabetes.org.uk [PDF] GT McMahon, RG Dluhy - The New England journal of medicine, 2007 - nejm.highwire.org The question of how to initiate insulin therapy in patients with type 2 diabetes
has become increasingly complicated as the range of insulin formulations with
differing time–activity profiles has expanded. Clinicians seeking to ... Cited by 19 - Related articles - BL Direct - All 11 versions
HC Gerstein, JF Yale, SB Harris, M Issa, JA … - DIABETIC MEDICINE-CHICHESTER-, 2006 - interscience.wiley.com Methods Consenting adults aged 18–80 years with Type 2 diabetes for at least 6
months, HbA 1c of 7.5–11%, and on 0, 1 or 2 oral agents, were randomized to
one of two therapeutic approaches for 24 weeks: evening insulin glargine ... Cited by 31 - Related articles - BL Direct - All 5 versions
HE Scholtz, SG Pretorius, DH Wessels, RHA … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: This single-dose, double- blind, randomised,
parallel-group study evaluated the reproducibility in systemic exposure and
glucodynamic effect of insulin glargine, NPH insulin (NPH) and insulin ... Cited by 61 - Related articles - BL Direct - All 3 versions
